Why entire system working to help pharmaceutical manufacturers, asks SC

The Supreme Court is examining whether the Centre is allowing medicine prices to remain unfairly high. Its main concern is the large gap between a medicine’s maximum retail price, or MRP, and the price charged to retailers. The bench said the government knows this is happening and asked whether the situation should be allowed to “run amok.”

The Centre argued that its policy is not to control the entire pharmaceutical ecosystem. Additional Solicitor General Aishwarya Bhati also told the court that medicine prices in India are among the lowest in the world. The judges, however, focused on how pricing works within the country and who benefits from the gap.

The court also questioned the effectiveness of the National Pharmaceutical Pricing Authority, calling it seemingly “totally defunct.” The matter involves two petitions about medicine pricing. The bench reserved its order, so the next legal direction remains pending.

MRP means maximum retail price. It is the highest price printed for a medicine’s sale to the patient. The price to retailers is the amount a retailer pays when obtaining the product from a manufacturer, distributor, or wholesaler. These are different points in the medicine’s supply chain.

The trade margin is the amount left between the price paid by a seller and the price at which the product is sold onward. For example, if a retailer pays ₹70 and sells a medicine at an MRP of ₹100, the difference is ₹30. Depending on how it is calculated, that may be described as a margin on the sale price or a markup on the buying price.

A large gap can create substantial earnings for supply-chain participants and raise patient costs. The article does not provide a typical or maximum gap. It reports only that the difference between MRP and retailer price is “massive,” which is why the court is examining trade-margin controls.

The article does not state how many rupees or what percentage separates the price to retailers from a medicine’s MRP. It describes the difference as “massive” and says the government is allowing it to happen under its own eyes. Therefore, the article cannot establish the largest possible gap or a representative average.

The court’s concern is that a low supply price can coexist with a much higher printed MRP. That gap may include margins earned by participants between the manufacturer and patient. The exact commercial breakdown is not given in the report, so the size of any individual participant’s margin cannot be calculated from it.

For anti-cancer medicines, the Centre said it had decided to cap the trade margin at 30% of MRP. It estimated that this measure would produce annual savings of approximately ₹2,500 crore for patients. The court had earlier questioned why similar controls could not cover other medicines.

The National Pharmaceutical Pricing Authority, or NPPA, is India’s government pricing regulator for medicines. Its broad purpose is to implement pharmaceutical-pricing policy, monitor prices, and help ensure that regulated medicines do not exceed permitted price limits. Those functions make it important when patients face unaffordable or unexplained medicine prices.

In this case, the Supreme Court was concerned about the large difference between medicine MRPs and the prices paid by retailers. That gap raised questions about whether pricing rules are being enforced effectively. The article does not describe a specific NPPA investigation, order, or enforcement action connected to the two petitions.

The bench said the NPPA seemed “totally defunct,” a sharp criticism of its apparent performance. The observation signals concern that the body may not be adequately checking medicine pricing. The court reserved its order, so the article does not state what reforms or directions will follow.

When medicine trade margins and MRPs remain high, patients may pay more at the point of purchase. This matters especially for people who need repeated or long-term treatment. A higher medicine bill can make care harder to afford, although this article does not provide patient surveys or measured health outcomes.

The pricing chain can contain several commercial layers. Manufacturers sell to distributors sell to retailers, and retailers sell to patients. If the final MRP is far above the retailer’s purchase price, the difference can support large margins somewhere in that chain. The article identifies the gap but does not allocate it among participants.

At the system level, unresolved price gaps can raise questions about whether regulation is working. The Supreme Court openly challenged the government’s oversight and the NPPA’s effectiveness. The Centre highlighted low medicine prices overall, while the court focused on the specific gap. Its reserved order may determine the next steps.

The article gives one stated policy reason for the limited approach: the Centre said its policy is that the entire pharmaceutical ecosystem is not to be controlled. It also presented the anti-cancer decision as an important targeted measure. The report does not give a fuller explanation for excluding other medicines from the same cap.

The Centre said anti-cancer trade margins would be capped at 30% of MRP. It expected this step to save patients approximately ₹2,500 crore each year. The measure followed severe criticism from the Supreme Court over steep markups on cancer drugs by hospitals.

The judges then questioned why trade margins could not be capped for other medicines too. They had earlier described the Centre’s response as “hardly anything to be happy about.” The court reserved its order, so the article does not say whether broader caps will be ordered or adopted.

A medicine’s price is built through a sequence of sales. The manufacturer produces and sells it to a distributor or wholesaler. The distributor then sells it to a retailer. The retailer finally sells it to the patient, generally at or below the printed MRP. Each stage can involve costs and a commercial margin.

The key mechanism is the difference between one stage’s buying price and the next stage’s selling price. For example, a distributor may buy at one price and sell higher, while a retailer adds another margin before the patient purchase. The article focuses on the especially large difference between the retailer’s price and the MRP, but supplies no detailed price breakdown.

This structure explains why the court is examining the whole pricing chain rather than only manufacturers. The Centre says the entire ecosystem should not be controlled, while the court asks why the system appears to help manufacturers. The pending order could clarify what oversight is required.